Short-term effectiveness of intravitreal Ziv-Aflibercept for the treatment of macular edema secondary to retinal vein occlusion
DOI:
https://doi.org/10.20453/rmh.v36i4.6368Keywords:
Retinal vein occlusion, Macular edema, Intravitreal Injection, Angiogenesis inhibitorsAbstract
Objective: To determine the short-term effectiveness of intravitreal Ziv-Aflibercept (IV-ZA) for the treatment of macular edema secondary to retinal vein occlusion (MESRVO). Methods: A retrospective, single-arm cohort study was conducted, including patients diagnosed with MESRVO. All received six monthly doses of IV-ZA. Data was collected before treatment and one month after the final dose. The main outcome measures were best-corrected visual acuity (BCVA, LogMAR) and central macular thickness (CMT). Summary statistics were presented, and the Wilcoxon signed-rank test with continuity correction was used; p < 0.05 was considered statistically significant. Data were analyzed using R Studio. Results: Twenty-six eyes from 25 patients were included (69% with central retinal vein occlusion and 31% with branch retinal vein occlusion). Sixty-eight percent were male, with a mean age of 63.9 ± 13.4 years. Baseline BCVA was 2 (0.3–2.09) LogMAR, improving to 1 (0.09–2) LogMAR (p < 0.01). Baseline CMT was 671 (392–1174) µm, decreasing to 207 (137–325) µm after treatment (p < 0.01). A total of 92.3% of eyes achieved a CMT below 300 µm after therapy. No ocular or systemic adverse events were reported. Conclusions: Six-monthly doses of IV-ZA were effective for the short-term management of MESRVO, showing significant visual and anatomical improvement. IV-ZA may represent a safe and cost-effective therapeutic alternative.
Downloads
References
Andrade GC, Dias JRO, Maia A, Farah ME, Mitne S, Rodrigues EB. Intravitreal injections of Ziv-aflibercept for the treatment of a patient with macular edema secondary to branch retinal vein occlusion. Retin Cases Brief Rep. 2018;12(2):93-96. doi: 10.1097/ICB.0000000000000449.
Braimah IZ, Agyabeng K, Amoaku WM. Efficacy of intravitreal ziv-aflibercept in patients with macular edema following retinal vein occlusion in Korle-Bu Teaching Hospital, Ghana: a retrospective case series. Int Ophthalmol. 2021;41(7):2445-2453. doi: 10.1007/s10792-021-01799-w.
Eldeeb M, Chan EW, Dedhia CJ, Mansour A, Chhablani J. One-year outcomes of ziv-aflibercept for macular edema in central retinal vein occlusion. Am J Ophthalmol Case Rep. 2017; 8:58-61. doi: 10.1016/j.ajoc.2017.10.011.
Chan EW, Eldeeb M, Dedhia CJ, Mansour A, Chhablani J. One-year treatment outcomes of ziv-aflibercept for treatment-naïve macular oedema in branch retinal vein occlusion. Acta Ophthalmol. 2018;96(2): e256-e257. doi: 10.1111/aos.13432.
Braimah IZ, Singh SR, Uplanchiwar B, Mansour AM, Chhablani J. Bevacizumab versus Ziv-aflibercept in branch retinal vein occlusion. Indian J Ophthalmol. 2019;67(7):1109-1113. doi: 10.4103/ijo.IJO_1532_18.
Yeung L, Wu WC, Chuang LH, Wang NK, Lai CC. Novel optical coherence tomography angiography biomarker in branch retinal vein occlusion macular edema. Retina. 2019;39(10):1906-1916. doi: 10.1097/IAE.0000000000002264.
Sen P, Gurudas S, Ramu J, Patrao N, Chandra S, Rasheed R, Nicholson L, Peto T, Sivaprasad S, Hykin P. Predictors of Visual Acuity Outcomes after Anti-Vascular Endothelial Growth Factor Treatment for Macular Edema Secondary to Central Retinal Vein Occlusion. Ophthalmol Retina. 2021;5(11):1115-1124. doi: 10.1016/j.oret.2021.02.008.
Suzuki M, Nagai N, Minami S, Kurihara T, Kamoshita M, Sonobe H, Watanabe K, Shinoda H, Tsubota K, Ozawa Y. Predicting recurrences of macular edema due to branch retinal vein occlusion during anti-vascular endothelial growth factor therapy. Graefes Arch Clin Exp Ophthalmol. 2020;258(1):49-56. doi: 10.1007/s00417-019-04495-9.
Yiu G, Welch RJ, Wang Y, Wang Z, Wang PW, Haskova Z. Spectral-Domain OCT Predictors of Visual Outcomes after Ranibizumab Treatment for Macular Edema Resulting from Retinal Vein Occlusion. Ophthalmol Retina. 2020;4(1):67-76. doi: 10.1016/j.oret.2019.08.009.
Paulose R, Chhablani J, Dedhia CJ, Stewart MW, Mansour AM. Intravitreal ziv-aflibercept for macular edema following retinal vein occlusion. Clin Ophthalmol. 2016; 10:1853-1858. doi: 10.2147/OPTH.S116343.
Lashay A, Riazi-Esfahani H, Mirghorbani M, Yaseri M. Intravitreal Medications for Retinal Vein Occlusion: Systematic Review and Meta-analysis. J Ophthalmic Vis Res. 2019;14(3):336-366. doi: 10.18502/jovr.v14i3.4791.
Singh SR, Stewart MW, Chattannavar G, Ashraf M, et al. Safety of 5914 intravitreal Ziv-aflibercept injections. Br J Ophthalmol. 2019;103(6):805-810. doi: 10.1136/bjophthalmol-2018-312453.
Hernandez-Da Mota SE, Melo-Granados EAR, Fromow-Guerra J, Bejar-Cornejo F, Gallego-Pinazo R, Rodríguez-Ayala E. Correlation analysis of fundus autofluorescence, spectral domain optical coherence tomography, and visual function in patients with diabetic macular oedema treated with intravitreal ziv-aflibercept. Eur J Ophthalmol. 2019;29(3):271–7. doi: 10.1177/1120672119833267.
Jabbarpoor Bonyadi MH, Baghi A, Ramezani A, Yaseri M, Soheilian M. One-Year Results of a Trial Comparing 2 Doses of Intravitreal Ziv-aflibercept versus Bevacizumab for Treatment of Diabetic Macular Edema. Ophthalmol Retina. 2018;2(5):428–40. Doi: 10.1016/j.oret.2017.09.010.
Mansour AM, Ashraf M, Charbaji A, Younis MH, Souka AA, Dogra A, Mansour HA, Chhablani J; Ziv-aflibercept study group investigators. Two-year outcomes of intravitreal ziv-aflibercept. Br J Ophthalmol. 2018;102(10):1387-1390. doi: 10.1136/bjophthalmol-2017-311591.
Mansour AM, Stewart MW, Farah ME, Mansour HA, Chhablani J. Ziv-aflibercept: A cost-effective, off-label, highly potent antagonist of vascular endothelial growth factor. Acta Ophthalmol. 2020;98(5):e540-e548. doi: 10.1111/aos.14328.
Chhablani J, Narayanan R, Mathai A, Yogi R, Stewart M. Short-term safety profile of intravitreal Ziv-Aflibercept. Retina. 2016;36(6):1126-31. doi: 10.1097/IAE.0000000000000913.
Singh SR, Dogra A, Stewart M, Das T, Chhablani J. Intravitreal Ziv-Aflibercept: Clinical Effects and Economic Impact. Asia Pac J Ophthalmol (Phila). 2017;6(6):561-568. doi: 10.22608/APO.2017263
Potter MJ, Szabo SM, Li WW. Comparison of visual acuity outcomes in predominantly classic vs occult lesions in age-related macular degeneration treated with photodynamic therapy. Eye. 2008;22(2):194–9. doi: 10.1038/sj.eye.6702547.
Ding X, Hu Y, Yu H, Li Q. Changes of Optical Coherence Tomography Biomarkers in Macular Edema Secondary to Retinal Vein Occlusion After Anti-VEGF and Anti-Inflammatory Therapies. Drug Des Devel Ther. 2022; 16:717–25. doi: 10.2147/DDDT.S351683.
Otawa T, Noma H, Yasuda K, Narimatsu A, Asakage M, Tanaka A, Goto H, Shimura M. Intravitreal ranibizumab improves macular sensitivity in patients with central retinal vein occlusion and macula edema. BMC Ophthalmol. 2022;22(1):247. doi: 10.1186/s12886-022-02478-9.
Gao S, Zhang Y, Li X, Ge G, Duan J, Lei C, Zeng Y, Cai Z, Zhang M. Comparative Efficacy of Pharmacotherapy for Macular Edema Secondary to Retinal Vein Occlusion: A Network Meta-analysis. Front Pharmacol. 2021; 12:752048. doi: 10.3389/fphar.2021.752048.
HodjatJalali K, Mehravaran S, Faghihi H, Hashemi H, Kazemi P, Rastad H. Intravitreal injection of ziv-aflibercept in the treatment of choroidal and retinal vascular diseases. J Curr Ophthalmol. 2017;29(3):228-231. doi: 10.1016/j.joco.2017.01.005.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Los autores
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors assign their rights to the RMH so that may disseminate the article through the means at their disposal. The journal will provide forms of affidavit of authorship and authorization for the publication of the article, which shall be submitted with the manuscript. Authors retain the right to share, copy, distribute, perform and publicly communicate their article, or part of it, mentioning the original publication in the journal.
